when will semaglutide become generic Demand Rising for 'Bootlegged' Weight-Loss Drug Dr Reddy's gets regulatory nod

When you move from a match slip to a live roulette round, the interface should preserve bet context without duplicating prompts

Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies

GLP-1R, a core member of the GPCR family, is widely present on the surfaces of various cells in the human body.1,2 By specifically binding to the key hormone GLP-1, it regulates blood glucose levels and lipid metabolism.3,4 This receptor and its agonists hold significant therapeutic potential, reshaping the treatment approaches for multiple diseases, including diabetes, cardiovascular disorders, and neurodegenerative diseases .5,6,7 GLP-1 is a peptide produced by the cleavage of proglucagon, mainly synthesized in the intestinal mucosal L-cells, pancreatic islet -cells, and neurons in the nucleus of the solitary tract.3,4 GLP-1RAs mimic the action of endogenous GLP-1, activating GLP-1R, thereby enhancing insulin secretion, inhibiting glucagon release, delaying gastric emptying, and reducing food intake through central appetite suppression.8,9,10 These mechanisms make GLP-1RAs powerful tools for controlling blood glucose and improving metabolic syndrome

Pregnant or breastfeeding women are also advised against it, as safety data in these groups remains insufficient

Gallbladder disease, retinopathy and severe hypoglycaemia did not differ significantly between the semaglutide and placebo groups

Patients in whom heart failure (HF) or chronic kidney disease (CKD) is prevalent, should receive a treatment intensification with an SGLT-2 inhibitor with the respective evidence from clinical studies due to the respective data (7072)